RAPS: FDA Issues Guidance on \'Substantial Equivalence\' Process Used to Bring Devices to Market

The US Food and Drug Administration (FDA) has issued an extensive and long-awaited guidance document on its premarket notification program—also known as the 510(k) pathway—detailing how regulators will evaluate applications in order to determine \"substantial equivalence.\"